You are here: Industry Insights > Rheumatoid Arthritis

News List

European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Se lilly
February 14, 2017
Eli Lilly and Company announced today that the European Commission has granted marketing authorisation for Olumiant® (baricitinib) 4 mg and 2 mg film-coated tablets in Europe for the treatment of moderate-to-severe active rheumatoid arthritis (RA)...
FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment americanpharmaceuticalreview
January 18, 2017
Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the new drug application (NDA) for investigational baricitinib, a once-daily oral medication for the treatment
US FDA extends review period for Eli Lilly and Incyte’s rheumatoid arthritis treatment pharmaceutical-technology
January 17, 2017
The US Food and Drug Administration (FDA) has extended the review period for the new drug application (NDA) for Eli Lilly and Incyte’s investigational baricitinib used to treat patients suffering from moderate-to-severe rheumatoid arthritis (RA).
FDA extends review period for Eli Lilly’s rheumatoid arthritis drug europeanpharmaceuticalreview
January 17, 2017
The US Food and Drug Administration (FDA) has extended the review period for Eli Lilly and Incyte’s new drug application for investigational baricitinib, a once-daily oral medication for the treatment of moderate to severe rheumatoid arthritis (RA).
U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment lilly
January 16, 2017
Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the new drug application (NDA) for investigational baricitinib.

Previous page 1 2 3 4 5 6 Next page